Clinical Trial Update: Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for autologous endothelial progenitor cell therapy aimed at reversing liver cirrhosis in end-stage liver disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Liver Disease
• Liver Cirrhosis

Drugs mentioned

• Autologous Endothelial Progenitor Cell Therapy

Snippet

Sponsor: National University Hospital, Singapore | Conditions: End Stage Liver Disease | Phase 3 | Status: UNKNOWN